Cizzle Biotechnology has been granted Canadian patent protection for methods measuring the CIZ1B lung cancer biomarker, strengthening its intellectual property portfolio...
Cizzle Biotechnology Chairman Derek Bickerstaff has confirmed the company has signed a Letter of Intent with a confidential NHS-affiliated diagnostics partner...
Cizzle Biotechnology has signed a letter of intent with an NHS-linked diagnostics partner to begin UK validation of its CIZ1B lung cancer test. Executive Chairman Dr Allan Syms outlines how this complements their existing US licence and supports national early detection targets...
Cizzle Biotechnology has signed a Letter of Intent with a leading UK medical diagnostics provider working with the NHS to verify and validate its CIZ1B biomarker test for early lung cancer detection...
Cizzle Biotechnology Executive Chairman Dr Allan Syms spoke with DirectorsTalk about the company’s interim results and progress in commercialising its CIZ1B blood test for the early detection of lung cancer...
Cizzle Biotechnology is now in commercial motion, with its lung cancer diagnostic test entering clinical validation across North America. Backed by Cizzle Bio, OmniHealth, and the Moffitt Cancer Center, the company is moving from lab bench to nationwide rollout — with royalty payments already in hand...
Cizzle Biotechnology has confirmed further progress in the US launch of its CIZ1B biomarker test through exclusive partner Cizzle Bio Inc, which is completing validation with Omni Health Diagnostics...
Cizzle Biotechnology has announced that its North American partner, Cizzle Bio Inc, has signed an agreement with a multi-site accredited laboratory group to roll out the CIZ1B biomarker test for early lung cancer detection across the USA...
Cizzle Biotechnology Holdings Plc has raised £150,000 to advance its CIZ1B early cancer test, enhancing access to innovative diagnostics in the UK and Europe...
Cizzle Biotechnology announces significant strides in early lung cancer detection through its partner's first Caribbean contract, boosting its biomarker test rollout...
Cizzle Biotechnology Holdings plc has launched a new corporate website, enhancing access to vital information about its early cancer tests and growth strategy...
Cizzle Biotechnology appoints Matt Bower as Non-Executive Director, enhancing its board for growth as it prepares to launch innovative cancer tests globally...
Cizzle Biotechnology announces a breakthrough in early lung cancer detection with iGenomeDX appointed to launch the CIZ1B biomarker test across the USA...
Cizzle Biotechnology names Professor Dawn Coverley as Chief Scientific Officer, marking a strategic shift. She will focus on advancing the CIZ1B biomarker assay...
Cizzle Biotechnology Holdings PLC reports successful fundraising, key partnerships, and advancements in early lung cancer detection, reflecting strong progress in H1 2024...
Cizzle Biotechnology has been granted Canadian patent protection for methods measuring the CIZ1B lung cancer biomarker, strengthening its intellectual property portfolio...
Cizzle Biotechnology Chairman Derek Bickerstaff has confirmed the company has signed a Letter of Intent with a confidential NHS-affiliated diagnostics partner...
Cizzle Biotechnology has signed a letter of intent with an NHS-linked diagnostics partner to begin UK validation of its CIZ1B lung cancer test. Executive Chairman Dr Allan Syms outlines how this complements their existing US licence and supports national early detection targets...
Cizzle Biotechnology has signed a Letter of Intent with a leading UK medical diagnostics provider working with the NHS to verify and validate its CIZ1B biomarker test for early lung cancer detection...
Cizzle Biotechnology Executive Chairman Dr Allan Syms spoke with DirectorsTalk about the company’s interim results and progress in commercialising its CIZ1B blood test for the early detection of lung cancer...
Cizzle Biotechnology is now in commercial motion, with its lung cancer diagnostic test entering clinical validation across North America. Backed by Cizzle Bio, OmniHealth, and the Moffitt Cancer Center, the company is moving from lab bench to nationwide rollout — with royalty payments already in hand...
Cizzle Biotechnology has confirmed further progress in the US launch of its CIZ1B biomarker test through exclusive partner Cizzle Bio Inc, which is completing validation with Omni Health Diagnostics...
Cizzle Biotechnology has announced that its North American partner, Cizzle Bio Inc, has signed an agreement with a multi-site accredited laboratory group to roll out the CIZ1B biomarker test for early lung cancer detection across the USA...
Cizzle Biotechnology Holdings Plc has raised £150,000 to advance its CIZ1B early cancer test, enhancing access to innovative diagnostics in the UK and Europe...
Cizzle Biotechnology announces significant strides in early lung cancer detection through its partner's first Caribbean contract, boosting its biomarker test rollout...
Cizzle Biotechnology Holdings plc has launched a new corporate website, enhancing access to vital information about its early cancer tests and growth strategy...
Cizzle Biotechnology appoints Matt Bower as Non-Executive Director, enhancing its board for growth as it prepares to launch innovative cancer tests globally...
Cizzle Biotechnology announces a breakthrough in early lung cancer detection with iGenomeDX appointed to launch the CIZ1B biomarker test across the USA...
Cizzle Biotechnology names Professor Dawn Coverley as Chief Scientific Officer, marking a strategic shift. She will focus on advancing the CIZ1B biomarker assay...
Cizzle Biotechnology Holdings PLC reports successful fundraising, key partnerships, and advancements in early lung cancer detection, reflecting strong progress in H1 2024...
